Study Supplement: OEA for Gulf War Illness
Phase-Based Progress Estimates
Effectiveness
Safety
Gulf War Illness
Oleoylethanolamide (OEA) - DietarySupplementEligibility
Any Age
All Sexes
What conditions do you have?
Select
Eligibility
Any Age
All Sexes
What conditions do you have?
Select
Study Summary
This trial is studying OEA to see if it can help treat symptoms in people with Gulf War Illness.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 6 Secondary · Reporting Duration: 10 weeks
10 weeks
Cognition
Changes in cognition (neuropsychological)
Changes in fatigue
Changes in immune biomarker profiles
Changes in lipid biomarker profiles
Changes in mood
Pain
Changes in quality of life
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Study Supplement: OEA
1 of 2
Control
1 of 2
Active Control
Non-Treatment Group
52 Total Participants · 2 Treatment Groups
Primary Treatment: Study Supplement: OEA · Has Placebo Group · N/A
Control
DietarySupplement
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: DietarySupplementStudy Supplement: OEA
DietarySupplement
ActiveComparator Group · 1 Intervention: Oleoylethanolamide (OEA) · Intervention Types: DietarySupplementTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 10 weeks
Who is running the clinical trial?
Roskamp Institute Inc.Lead Sponsor
5 Previous Clinical Trials
374 Total Patients Enrolled
2 Trials studying Gulf War Illness
128 Patients Enrolled for Gulf War Illness
United States Department of DefenseFED
767 Previous Clinical Trials
202,353 Total Patients Enrolled
11 Trials studying Gulf War Illness
668 Patients Enrolled for Gulf War Illness
Laila Abdullah, PhDPrincipal InvestigatorThe Roskamp Insitute
2 Previous Clinical Trials
128 Total Patients Enrolled
2 Trials studying Gulf War Illness
128 Patients Enrolled for Gulf War Illness
Andrew Keegan, MDPrincipal InvestigatorThe Roskamp Insitute
1 Previous Clinical Trials
52 Total Patients Enrolled
1 Trials studying Gulf War Illness
52 Patients Enrolled for Gulf War Illness
Eligibility Criteria
Age Any Age · All Participants · 8 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You are both male and female, of all ethnic groups, and all ages.
Veteran has chronic multisymptom illness.
You are 50.0kg (110lbs) or more.\n
You are of reproductive age and willing to use an acceptable form of birth control for 30 days after the last dose.
You were deployed to the Gulf War between August 1990 and August 1991.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
References
- White, Roberta F., Lea Steele, James P. O'Callaghan, Kimberly Sullivan, James H. Binns, Beatrice A. Golomb, Floyd E. Bloom, et al.. 2016. “Recent Research on Gulf War Illness and Other Health Problems in Veterans of the 1991 Gulf War: Effects of Toxicant Exposures During Deployment”. Cortex. Elsevier BV. doi:10.1016/j.cortex.2015.08.022.
- Emmerich, Tanja, Zuchra Zakirova, Nancy Klimas, Kimberly Sullivan, Ashok K. Shetty, James E. Evans, Ghania Ait-Ghezala, et al.. 2017. “Phospholipid Profiling of Plasma from GW Veterans and Rodent Models to Identify Potential Biomarkers of Gulf War Illness”. Edited by Alexandra Kavushansky. Plos One. Public Library of Science (PLoS). doi:10.1371/journal.pone.0176634.
- Joshi, Utsav, James E. Evans, Ross Joseph, Tanja Emmerich, Nicole Saltiel, Carlyn Lungmus, Sarah Oberlin, et al.. 2018. “Oleoylethanolamide Treatment Reduces Neurobehavioral Deficits and Brain Pathology in a Mouse Model of Gulf War Illness”. Scientific Reports. Springer Science and Business Media LLC. doi:10.1038/s41598-018-31242-7.
- Abdullah, Laila, James E. Evans, Hannah Montague, Jon M. Reed, Ann Moser, Gogce Crynen, Ariel Gonzalez, et al.. 2013. “Chronic Elevation of Phosphocholine Containing Lipids in Mice Exposed to Gulf War Agents Pyridostigmine Bromide and Permethrin”. Neurotoxicology and Teratology. Elsevier BV. doi:10.1016/j.ntt.2013.10.002.
- Abdullah, Laila, James E. Evans, Alex Bishop, Jon M. Reed, Gogce Crynen, John Phillips, Robert Pelot, et al.. 2012. “Lipidomic Profiling of Phosphocholine Containing Brain Lipids in Mice with Sensorimotor Deficits and Anxiety-like Features After Exposure to Gulf War Agents”. Neuromolecular Medicine. Springer Science and Business Media LLC. doi:10.1007/s12017-012-8192-z.
- Abdullah, Laila, Gogce Crynen, Jon Reed, Alex Bishop, John Phillips, Scott Ferguson, Benoit Mouzon, et al.. 2011. “Proteomic CNS Profile of Delayed Cognitive Impairment in Mice Exposed to Gulf War Agents”. Neuromolecular Medicine. Springer Science and Business Media LLC. doi:10.1007/s12017-011-8160-z.
- Abdullah, Laila, James E. Evans, Utsav Joshi, Gogce Crynen, Jon Reed, Benoit Mouzon, Stephan Baumann, et al.. 2016. “Translational Potential of Long-term Decreases in Mitochondrial Lipids in a Mouse Model of Gulf War Illness”. Toxicology. Elsevier BV. doi:10.1016/j.tox.2016.10.012.
- 2021. "OEA for Targeting Lipid Metabolism in GWI". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05252949.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments